SGMO
SANGAMO THERAPEUTICS, INC
NASDAQ · Healthcare · Biotechnology · US
$0.07
+0.00%Sep 21, 2026, 20:06 UTC
Sangamo Therapeutics sold substantially all assets related to its gene therapy candidate ST-920 (isaralgagene civaparvovec) to PTC Therapeutics for $111 million in cash at closing, up to $100 million in contingent milestones, and assumption of specified liabilities.
Aug 28, 2026, 20:21 UTC
PTC Therapeutics agreed to acquire from Sangamo Therapeutics all rights to ST-920, an AAV gene therapy product candidate for Fabry disease, for an upfront payment of $111 million plus up to $100 million in contingent milestone payments.
Aug 12, 2026, 20:01 UTC
PTC Therapeutics announced a planned acquisition of Sangamo Therapeutics' BLA-stage ST-920 Fabry disease gene therapy program, leveraging existing regulatory and commercial infrastructure.
Jun 23, 2026, 00:00 UTC
Sangamo Therapeutics filed for Chapter 11 bankruptcy and signed stalking horse asset purchase agreements with Eli Lilly and Astellas to sell its assets in a bankruptcy auction.